174 related articles for article (PubMed ID: 29976459)
1. Alzheimer's disease research: the future of BACE inhibitors.
Burki T
Lancet; 2018 Jun; 391(10139):2486. PubMed ID: 29976459
[No Abstract] [Full Text] [Related]
2. Deal watch: Lilly buys back into the BACE race for Alzheimer's disease.
Cully M
Nat Rev Drug Discov; 2014 Nov; 13(11):804. PubMed ID: 25323931
[No Abstract] [Full Text] [Related]
3. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity.
Evin G; Lessene G; Wilkins S
Recent Pat CNS Drug Discov; 2011 May; 6(2):91-106. PubMed ID: 21585329
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.
Crunkhorn S
Nat Rev Drug Discov; 2016 Dec; 16(1):18. PubMed ID: 28031572
[No Abstract] [Full Text] [Related]
5. The potential of BACE inhibitors for Alzheimer's therapy.
Potter H; Dressler D
Nat Biotechnol; 2000 Feb; 18(2):125-6. PubMed ID: 10657070
[No Abstract] [Full Text] [Related]
6. BACE inhibitor bust in Alzheimer trial.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
[No Abstract] [Full Text] [Related]
7. New N(4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors.
Laras Y; Garino C; Dessolin J; Weck C; Moret V; Rolland A; Kraus JL
J Enzyme Inhib Med Chem; 2009 Feb; 24(1):181-7. PubMed ID: 18770069
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease and other dementias: update on research.
Schneider L
Lancet Neurol; 2017 Jan; 16(1):4-5. PubMed ID: 27979354
[No Abstract] [Full Text] [Related]
9. Progress toward a practical BACE-1 inhibitor.
Hills ID; Vacca JP
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):383-91. PubMed ID: 17659479
[TBL] [Abstract][Full Text] [Related]
10. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
11. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
Semighini EP
Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
[TBL] [Abstract][Full Text] [Related]
12. Design and development of BACE-1 inhibitors.
Cumming JN; Iserloh U; Kennedy ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):536-56. PubMed ID: 15338962
[TBL] [Abstract][Full Text] [Related]
13. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Shitaka Y; Mitani Y; Nagakura A; Miyake A; Matsuoka N
Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):15-20. PubMed ID: 20628208
[No Abstract] [Full Text] [Related]
15. The evolution of amidine-based brain penetrant BACE1 inhibitors.
Oehlrich D; Prokopcova H; Gijsen HJ
Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
[TBL] [Abstract][Full Text] [Related]
16. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
17. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.
Vellas B; Bain LJ; Touchon J; Aisen PS
J Prev Alzheimers Dis; 2019; 6(3):198-203. PubMed ID: 31062835
[TBL] [Abstract][Full Text] [Related]
18. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
Kumar A; Srivastava G; Sharma A
Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
[TBL] [Abstract][Full Text] [Related]
19. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Alzheimer's BACE-1 with 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridine structure.
Miri R; Firuzi O; Razzaghi-Asl N; Javidnia K; Edraki N
Arch Pharm Res; 2015 Apr; 38(4):456-69. PubMed ID: 24771353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
